Why are you placing double quotes around excellent clinical trial updates??? You don't think they were excellent???? Even the lead presenter Tweet about the efficacy seen so early in Ph1 clinical trial.
IMU has told us the direction but you clearly aren't listening, partner or license Ph3 clinical trials as they are way too expensive to go it alone but I think PH want to sell the entire company like he did with VLA. Everyone had the opportunity to sell even as recently as at 15c from 4c, is that not return to share holders???? I didn't as I'm investing for the big return and thought that was the catalyst for a massive re-rate since seeing any kind of efficacy so early in Ph1 clinical trial with such low dosage is very rare which was why the FDA granted Fast Track designation and ODD so quickly within 12-18 months of clinical trial and initially the market did as well. That's why I said there's a big disconnect between the fundamental especially after the excellent clinical trial update for Azer-Cel 3 months ago.
IMU Price at posting:
3.6¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)